| Revenue growth | 23.4% Y-o-Y for pharmacy operations. |
|---|---|
| Margins | Consolidated EBITDA 5.8%; mature stores (12m+) at 13.1% store-level EBITDA. |
| Demand visibility | Stable; driven by network densification and omnichannel convenience. |
| Management confidence | High; intent to stabilize and grow margins through private label mix. |
Growth
Pharmacy revenue grew 23.4% Y-o-Y. Private label sales reached 22% of total revenue. Diagnostics segment grew to INR 347.8 million.
Outlook
Guided 800 net new stores for FY27. Targeting 9-10% annualized SSSG and maintaining 5.7-5.8% EBITDA margins while scaling private labels.
Risks
Higher store closures (77 in Q4) primarily due to underperformance in older stores and relocation. Private label scaling depends on customer conversion.
Earnings Call filed with NSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹654.90
- Market cap
- ₹7,868 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 37.4×Sector 57.8×
- Promoter holding
- 40.19%-0.03% QoQ
- FII holding
- 14.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
- Value
- ₹0.01 Cr
- From
- Drugs Control Administration, Haveri Circle, Karnataka
Medplus Health Services Legal & Regulatory
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
- Value
- ₹0.01 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
- Value
- ₹0.02 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
- Value
- ₹0.10 Cr
Medplus Health Services Adverse Business Impact
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Execution
- 7 days
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
- Value
- ₹0.10 Cr
- Execution
- 5 to 15 days